161 related articles for article (PubMed ID: 37144736)
1. Risk of Acute Kidney Injury Based on Vancomycin Target Trough Attainment Strategy: Area-Under-the-Curve-Guided Bayesian Software, Nomogram, or Trough-Guided Dosing.
Knight JM; Iso T; Perez KK; Swan JT; Janak CE; Ikwuagwu JO; Musick WL
Ann Pharmacother; 2024 Feb; 58(2):110-117. PubMed ID: 37144736
[TBL] [Abstract][Full Text] [Related]
2. Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: Systematic review and meta-analysis.
Abdelmessih E; Patel N; Vekaria J; Crovetto B; SanFilippo S; Adams C; Brunetti L
Pharmacotherapy; 2022 Sep; 42(9):741-753. PubMed ID: 35869689
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of area under the concentration-time curve-guided vancomycin dosing with or without piperacillin-tazobactam on the incidence of acute kidney injury.
Muklewicz JD; Steuber TD; Edwards JD
Int J Antimicrob Agents; 2021 Jan; 57(1):106234. PubMed ID: 33232734
[TBL] [Abstract][Full Text] [Related]
4. Implementation of vancomycin AUC/MIC dosing vs traditional trough dosing and incidence of acute kidney injury at a rural community hospital.
McClure S; McElroy L; Gugkaeva Z
Am J Health Syst Pharm; 2024 May; 81(11):e283-e288. PubMed ID: 38253056
[TBL] [Abstract][Full Text] [Related]
5. Conversion from Vancomycin Trough Concentration-Guided Dosing to Area Under the Curve-Guided Dosing Using Two Sample Measurements in Adults: Implementation at an Academic Medical Center.
Meng L; Wong T; Huang S; Mui E; Nguyen V; Espinosa G; Desai J; Holubar M; Deresinski S
Pharmacotherapy; 2019 Apr; 39(4):433-442. PubMed ID: 30739349
[TBL] [Abstract][Full Text] [Related]
6. Cost-benefit analysis comparing trough, two-level AUC and Bayesian AUC dosing for vancomycin.
Lee BV; Fong G; Bolaris M; Neely M; Minejima E; Kang A; Lee G; Gong CL
Clin Microbiol Infect; 2021 Sep; 27(9):1346.e1-1346.e7. PubMed ID: 33221430
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Vancomycin Bayesian-Estimated Area Under the Curve Versus Trough-Based Dosing.
Cerenzio J; Truong J
Ann Pharmacother; 2023 Aug; 57(8):931-939. PubMed ID: 36476049
[TBL] [Abstract][Full Text] [Related]
8. The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing.
Tsutsuura M; Moriyama H; Kojima N; Mizukami Y; Tashiro S; Osa S; Enoki Y; Taguchi K; Oda K; Fujii S; Takahashi Y; Hamada Y; Kimura T; Takesue Y; Matsumoto K
BMC Infect Dis; 2021 Feb; 21(1):153. PubMed ID: 33549035
[TBL] [Abstract][Full Text] [Related]
9. Reduced nephrotoxicity with vancomycin therapeutic drug monitoring guided by area under the concentration-time curve against a trough 15-20 μg/mL concentration.
Oda K; Jono H; Nosaka K; Saito H
Int J Antimicrob Agents; 2020 Oct; 56(4):106109. PubMed ID: 32721597
[TBL] [Abstract][Full Text] [Related]
10. A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity.
Finch NA; Zasowski EJ; Murray KP; Mynatt RP; Zhao JJ; Yost R; Pogue JM; Rybak MJ
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923869
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the incidence of vancomycin-associated nephrotoxicity following the change from trough-guided dosing to AUC-guided doing using trough-only data.
Yamada Y; Niwa T; Ono Y; Yamada S; Niwa K; Yasue M; Yamamoto T; Sumi K; Otsubo M; Kobayashi R; Suzuki A
J Antimicrob Chemother; 2023 Dec; 78(12):2933-2937. PubMed ID: 37889089
[TBL] [Abstract][Full Text] [Related]
12. Outpatient vancomycin therapy: Acute kidney injury in individualized AUC-based goal trough ranges versus traditional trough dosing.
Rees MR; Carr DR; Trienski T; Buchanan C; White K; Bremmer DN
J Am Pharm Assoc (2003); 2022; 62(3):706-710. PubMed ID: 34920955
[TBL] [Abstract][Full Text] [Related]
13. VANCOmycin dose adjustments comparing trough levels to the ratio of the area under de curve to the minimum inhibitory concentration method using a BAYESian approach: A feasibility study.
Bilodeau V; Huot J; Perreault C; Haraoui LP; Delorme C; Poudrette J; Marsot A; Crevier B
J Clin Pharm Ther; 2022 Dec; 47(12):2335-2344. PubMed ID: 36461655
[TBL] [Abstract][Full Text] [Related]
14. Acute Kidney Injury Incidence With Bayesian Dosing Software Versus 2-Level First-Order Area Under the Curve-Based Dosing of Vancomycin With Piperacillin-Tazobactam.
Bellamy A; Covington EW
J Pharm Technol; 2023 Aug; 39(4):183-190. PubMed ID: 37529152
[No Abstract] [Full Text] [Related]
15. Candidates for area under the concentration-time curve (AUC)-guided dosing and risk reduction based on analyses of risk factors associated with nephrotoxicity in vancomycin-treated patients.
Hashimoto N; Kimura T; Hamada Y; Niwa T; Hanai Y; Chuma M; Fujii S; Matsumoto K; Shigemi A; Kawamura H; Takahashi Y; Takesue Y
J Glob Antimicrob Resist; 2021 Dec; 27():12-19. PubMed ID: 34371241
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Vancomycin Area-Under-the-Curve Dosing Versus Trough Target-Based Dosing in Obese and Nonobese Patients With Methicillin-Resistant
Covvey JR; Erickson O; Fiumara D; Mazzei K; Moszczenski Z; Slipak K; Nemecek BD; Zimmerman DE; Guarascio AJ
Ann Pharmacother; 2020 Jul; 54(7):644-651. PubMed ID: 31888350
[No Abstract] [Full Text] [Related]
17. First-Dose Vancomycin Pharmacokinetics Versus Empiric Dosing on Area-Under-the-Curve Target Attainment in Critically Ill Patients.
Flannery AH; Delozier NL; Effoe SA; Wallace KL; Cook AM; Burgess DS
Pharmacotherapy; 2020 Dec; 40(12):1210-1218. PubMed ID: 33176005
[TBL] [Abstract][Full Text] [Related]
18. Comparison of single trough-based area under the concentration-time curve versus trough concentration for the incidence of vancomycin-associated nephrotoxicity.
Niwa T; Yasue M; Harada S; Yamada Y; Otsubo M; Yamada M; Matsuoka S; Yamamoto T; Mizusaki Y; Suzuki A
J Infect Chemother; 2022 Jul; 28(7):923-928. PubMed ID: 35379525
[TBL] [Abstract][Full Text] [Related]
19. Establishment of an AUC
Chavada R; Ghosh N; Sandaradura I; Maley M; Van Hal SJ
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242672
[TBL] [Abstract][Full Text] [Related]
20. Retrospective Cohort Study of the Incidence of Acute Kidney Injury with Vancomycin Area under the Curve-Based Dosing with Concomitant Piperacillin-Tazobactam Compared to Meropenem or Cefepime.
Kiley PS; Pearston AP; Hodge LA; Kaplan MC; Baczek SM; Stanley JS; Wilson TJ; Soriano KM; Yao A; Shaeffer ZA; Talt IE; Cohen JA; Ingemi AI
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0004022. PubMed ID: 35867523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
